UNI-EN 11:Publishing of the Consolidated Audited Financial Statements for 2019 made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 11 | / | 2020 | |||||||
| Date of issue: | 2020-04-29 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Publishing of the Consolidated Audited Financial Statements for 2019 made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, April 6, 2020 – “Sopharma” AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that the Consolidated Audited Financial Statements for 2019 will be made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances. The delayed publishing of the Report is due to the extraordinary conditions in a number of countries in which the companies from the Group operate. Measures have been taken within the Company to decrease to a maximum the timeframe for finalizing and publishing of all documents part of the Report. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| 3JR_Consolidated_Audited_Extended_espi.pdf 3JR_Consolidated_Audited_Extended_espi.pdf | Publishing of the Consolidated Audited Financial Statements for 2019 made public in the terms envisaged in §45, item 2 of the TAP of the Law for the measures and actions under extraordinary circumstances | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2020-04-29 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 23.0 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
